Abiraterone acetate effective for males with advanced prostate cancer A drug recently approved by the meals & Medication Administration for the treatment of prostate cancer is proving to give some patients the gift of time. A fresh study displays abiraterone acetate extends the lives of men with the most advanced form of the disease by about four weeks. The scholarly research in the May 26, 2011 issue of the New England Journal of Medicine was co-authored by Thomas W. Flaig, MD, medical oncologist at the University of Colorado Hospital’s Tony Grampsas Urologic Oncology Clinic and associate professor at the University of Colorado College of Medication. ‘Abiraterone acetate is normally a new, life-extending pill for the treatment of advanced prostate cancer.Four days before cell infusion, the patient received chemotherapy designed for depletion of lymphocytes without rituximab.9 Three days after chemotherapy but before cell infusion, the bone marrow was hypercellular with around 40 percent involvement by CLL. Leukemia cellular material expressed kappa light chain and CD5, CD19, CD20, and CD23. Cytogenetic analysis showed two separate clones, both leading to loss of chromosome 17p and the TP53 locus /46,XY,dert/46,XY). No postinfusion cytokines had been administered. No toxic ramifications of infusions were noted. Clinical Response and Evaluations Fourteen days after the first infusion, the individual started having chills and low-grade fevers associated with grade 2 exhaustion.